However, if cancer cells are MCL-1 primed, to a greater or lesser degree, then the patients harboring those “primed to adapt” cancer cells might be steered to a treatment that could target the MCL-1:BIM complexes cells even before relapse from BCL-2:BIM targeting treatment. Here, BCL2L11 is linked to cancer.